Gene expression-based products for precision oncology

Liquid biopsy algorithm pipeline

Our ExpressCT™ pipeline brings gene expression to blood for almost any NGS workflow, advancing biomarkers across breast cancer subtype (ER, HER2, PR), lung histology, pan-cancer prognosis, PDAC molecular subtype, and platform-level reads including tumor fraction and tissue of origin.

Putting our powerful ExpressCT™ technology to work

Your program defines the targets. ExpressCT™ measures their expression from the sequencing data for an array of expression-based targets of interest.

Already have sequencing data or collecting it? Looking to develop a liquid biopsy counterpart for a tissue-based expression marker? We work with biopharma, diagnostics, technology, and CRO partners to enable this.

Extract more from retrospective data with ExpressCT Rewind™

• Submit FASTQ files from a banked CGP or WGS cohort. ExpressCT Rewind™ leverages the ExpressCT™ pipeline to return expression biomarker results — no new samples, no new assay.

Prospective integration

• Embed ExpressCT™ alongside your planned or ongoing study. Expression biomarkers run in parallel to mutations calling from the same sequencing data or from our custom cfDNA panel, GenomicsNext™, designed to maximize fragmentomic signals.

Partner with us

Tissue RNA algorithm pipeline

Grounded in RNA expression profiling, our tissue signatures inform therapy selection and prognosis across six cancer types. The portfolio is anchored by PurIST^®, our commercialized pancreatic cancer subtyping test, with additional signatures validated in published studies.